Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 9: EUROPA-Studie - Hypothese Abb. 10: EUROPA-Studie - Perindopril Abb. 11: EUROPA-Studie - Blutdruck Aktuelles Bild - Abb. 12: Perindopril - Gewebs-ACE Abb. 13: Perindopril - Bradykinin Abb. 14: Perindopril - Endotheliale Dysfunktion Abb. 15: Perindopril - Endothliale Dysfunktion Zum letzten Bild
Abbildung 12: Perindopril - Gewebs-ACE
Perindopril has a very high tissue and plasma ACE affinity, as proven for the first time ever with an ACEI in humans suffering from coronary artery disease. Zhuo et al. studied the in vivo effects of ACE inhibition with perindopril on cellular expression of ACE, in human blood vessels using quantitative in vitro autoradiography and immunocytochemistry. Perindopril decreased plasma ACE by 70 % and the plasma angiotensin II to angiotensin I ratio by 57 %, and reduced vascular ACE to approximately 65 % of control levels in both endothelium and adventitia. Perindopril inhibits both endothelial and advential ACE, this being further proof for reversing endothelial dysfunction, a key role player in the manifestation of cardiovascular diseases and their complications. This is one of the main reasons supporting its choice in the EUROPA study.
 
Perindopril - Gewebs-ACE
Vorheriges Bild Nächstes Bild   


Abbildung 12: Perindopril - Gewebs-ACE
Perindopril has a very high tissue and plasma ACE affinity, as proven for the first time ever with an ACEI in humans suffering from coronary artery disease. Zhuo et al. studied the in vivo effects of ACE inhibition with perindopril on cellular expression of ACE, in human blood vessels using quantitative in vitro autoradiography and immunocytochemistry. Perindopril decreased plasma ACE by 70 % and the plasma angiotensin II to angiotensin I ratio by 57 %, and reduced vascular ACE to approximately 65 % of control levels in both endothelium and adventitia. Perindopril inhibits both endothelial and advential ACE, this being further proof for reversing endothelial dysfunction, a key role player in the manifestation of cardiovascular diseases and their complications. This is one of the main reasons supporting its choice in the EUROPA study.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung